Mustang Bio: Rises on dosing first patient in early-stage brain tumor therapy study

Mustang Bio

18/05/2021 14:12

** Drug developer Mustang Bio's  MBIO.O  shares rise 5.9% to
$3.03 in premarket trade
    ** Co says first patient dosed in an early-stage clinical
trial to study its cell therapy for patients with types of brain
tumors  urn:newsml:reuters.com:*:nGNX1JzBGQ
    ** Trial, conducted with cancer treatment center City of
Hope where the cell therapy was initially developed, to enroll
up to 30 patients 
    ** All participants enrolled in the trial will undergo
surgery for placement of an intraventricular Rickham catheter -
co
    ** Says trial will study safety and feasibility of
administering the cell therapy, MB-101, through this catheter
over four weekly cycles 
    ** Up to last close MBIO stock down 24.4% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))